Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

AGM Statement

Cyprotex PLC ("Cyprotex" or the "Company")

Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:

"In 2009 we delivered a resilient performance in a difficult market. Revenues hit £5m for the second successive year and we also delivered our second year of profitability. We doubled the number of strategic customers and added 20 new customers in total.

"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."

Cyprotex expects to announce its interim results for the six months to 30 June 2010 on Thursday 12 August 2010.


For further information:
Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång
Tel: +44 203 205 7500
www.singercm.com

Financial Dynamics
Ben Brewerton / Ben Atwell / Mo Noonan
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close